| __timestamp | Genmab A/S | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 9335772 |
| Thursday, January 1, 2015 | 91224000 | 12390000 |
| Friday, January 1, 2016 | 102413000 | 25602000 |
| Sunday, January 1, 2017 | 146987000 | 21262000 |
| Monday, January 1, 2018 | 213695000 | 28430000 |
| Tuesday, January 1, 2019 | 342000000 | 40849000 |
| Wednesday, January 1, 2020 | 661000000 | 60210000 |
| Friday, January 1, 2021 | 1283000000 | 83664000 |
| Saturday, January 1, 2022 | 2676000000 | 104097000 |
| Sunday, January 1, 2023 | 3297000000 | 106916000 |
| Monday, January 1, 2024 | 3790000000 |
Cracking the code
In the ever-evolving biotech industry, operational efficiency is key. Over the past decade, Genmab A/S and Iovance Biotherapeutics, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab's SG&A expenses surged by an astounding 4,000%, reflecting its aggressive expansion and strategic investments. In contrast, Iovance's expenses grew by approximately 1,000%, indicating a more measured approach.
Genmab's expenses peaked in 2023, reaching nearly 30 times that of Iovance, highlighting its dominant market position. This stark difference underscores the varied strategies these companies employ to navigate the competitive landscape. As investors and industry watchers, understanding these financial dynamics offers a window into each company's operational priorities and future growth potential.
Eli Lilly and Company vs Genmab A/S: SG&A Expense Trends
Vertex Pharmaceuticals Incorporated vs Genmab A/S: SG&A Expense Trends
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Genmab A/S and Blueprint Medicines Corporation
Genmab A/S vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
CymaBay Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?